new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Glaxo Group Limited
Glaxo Group Limited A Corporation

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Glaxo Group Limited patents


      
Recent patent applications related to Glaxo Group Limited. Glaxo Group Limited is listed as an Agent/Assignee. Note: Glaxo Group Limited may have other listings under different names/spellings. We're not affiliated with Glaxo Group Limited, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Glaxo Group Limited-related inventors




Search recent Press Releases: Glaxo Group Limited-related press releases
Count Application # Date Glaxo Group Limited patents (updated weekly) - BOOKMARK this page
12016003044202/04/16  new patent  Novel compounds
22016002419701/28/16 Antibodies against amyloid-beta peptide
32016000971601/14/16 2 - (azaindol-2-yl) benz imidazoles as pad4 inhibitors
42016001011101/14/16 Production methods
52016000222001/07/16 Muscarinic acetylcholine receptor antagonists
62015036829212/24/15 Method of producing a protein
72015036103912/17/15 Sulfonamide compounds and their use in the modulation retinoid-related orphan receptor
82015036117612/17/15 Ligands that bind tgf-beta receptor ii
92015034289712/03/15 Polypeptide loaded poca nanoparticles for oral administration
102015034315912/03/15 Inhaler device
112015032804411/19/15 Guide device for a liquid dispenser
122015032822611/19/15 Novel compounds
132015031384111/05/15 Combination of umeclidinium, fluticasone propionate and salmeterol xinafoate for use in the treatment of inflammatory or respiratory tract diseases
142015030605810/29/15 Composition comprising a single variable domain and camostat mesylate (cm)
152015030748510/29/15 3 -amino- pyrazole derivatives useful against tuberculosis
162015029761410/22/15 Combination of levocabastine and fluticasone furoate for the treatment of inflammatory and/or allergic conditions
172015029912110/22/15 Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases
182015029917710/22/15 Novel polymorphs and salts
192015029922310/22/15 2-substituted cephem compounds
202015028445410/08/15 Anti-serum albumin binding variants
212015026553909/24/15 Formulation for retinoid-containing soft gelatin capsules
222015025114809/10/15 Container system for mixing and dispensing a drink
232015023847008/27/15 Muscarinic acetylcholine receptor antagonists
242015023242308/20/15 Chemical process
252015020917807/30/15 Liquid droplet dispenser
262015020931907/30/15 Compositions comprising an antibody and camostat mesylate (cm)
272015021076707/30/15 Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
282015021201607/30/15 Sample plate for an x-ray powder diffraction apparatus
292015020217207/23/15 Novel use
302015020385107/23/15 Inhibitors of bromodomain-containing protein pcaf for the treatment of autoimmune and inflammatory diseases or for the treatment of cancer
312015019756507/16/15 Novel ligand
322015018242707/02/15 Silica abrasive-free dentifrice composition
332015016650806/18/15 Novel compounds
342015015764006/11/15 Novel compounds
352015010817804/23/15 Re-sealable container
362015010538704/16/15 Substituted diketopiperazines and their use as oxytocin antagonists
372015009975604/09/15 Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp-pla2
382015009341404/02/15 Modified antigens
392015009344004/02/15 Aggregate nanoparticulate medicament formulations, manufacture and use thereof
402015008034303/19/15 Benzofuran compounds for the treatment of hepatitis c virus infections
412015008036903/19/15 Novel compounds
422015006420103/05/15 Antigen binding proteins to oncostatin m (osm)
432015006550703/05/15 Novel compounds
442015004537502/12/15 Novel compounds
452015000410501/01/15 Novel composition
462014037848712/25/14 Tricyclic compounds, preparation methods, and their uses
472014037126412/18/14 Muscarinic acetylcholine receptor antagonists
482014033508311/13/14 Methods of treatment and prevention of eye diseases
492014031197710/23/14 Use of organic solvent nanofiltration and liquid-liquid chromatography for the recovery of pharmaceutical products
502014028813309/25/14 3 -amino- pyrazole derivatives useful against tuberculosis
512014022725908/14/14 Modified proteins and peptides
522014022726408/14/14 Drug fusions and conjugates with extended half life
532014020560407/24/14 Antigen binding constructs
542014020566107/24/14 Formulation for retinoid-containing soft gelatin capsules
552014020021807/17/14 Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
562014019340707/10/14 Drug fusions and conjugates
572014018775007/03/14 Methods for selecting protease resistant polypeptides
582014017971506/26/14 2,3-dihydroimidazo[1 ,2-c] pyrimidin-5(1 h)-one compounds use as lp-pla2 inhibitors
592014015870406/12/14 Medicament dispenser
602014014099605/22/14 Anti-serum albumin biding variable domains
612014011643405/01/14 Dry powder inhaler compositions
622014011292904/24/14 Tumour necrosis factor receptor 1 antagonists
632014011388804/24/14 Novel combination of therapeutic agents
642014011392204/24/14 Compounds
652014010589404/17/14 Humanized anti-il-18 antibodies
662014010591504/17/14 Bcma (cd269/tnfrsf17) - binding proteins
672014007631403/20/14 Manifold for use in medicament dispenser
682014008086303/20/14 Muscarinic acetylcholine receptor antagonists
692014005690002/27/14 Method for inhibiting binding to b-cell receptor
702014005810502/27/14 Substituted diketopiperazines and their use as oxytocin antagonists
712014005071902/20/14 Antibodies
722014005172002/20/14 N-cyclobutyl - imidazopyridine - methylamine as trpv1 antagonists
732014003898902/06/14 Tetrahydropyrazolo [1,5-a] pyrimidine as anti-tuberculosis compounds
742014002359601/23/14 Novel composition
752014002455801/23/14 Method of treatment
762014000517701/02/14 Pyridinyl- and pyrazinyl-methyloxy-aryl derivatives useful as inhibitors of spleen tyrosine kinase (syk)
772014000518801/02/14 Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
782013034546512/26/13 Process for the preparation of retigabine
792013033698912/19/13 Methods of identifying a patient population
802013031590111/28/13 Novel uses
812013031704111/28/13 Compounds
822013031028111/21/13 Novel antigen binding proteins
832013030233511/14/13 Ligands that bind tgf-beta receptor ii
842013026771710/10/13 Process for the preparation of atovaquone
852013026118510/03/13 Benzamide derivatives as ep4 receptor agonists
862013025172409/26/13 Antigen binding proteins to oncostatin m (osm)
872013025318809/26/13 Novel compounds
882013023750109/12/13 Benzofuran compounds for the treatment of hepatitis c virus infections
892013022420408/29/13 Method of treatment based on atad2 inhibitors
902013021315408/22/13 Method of determining cleanliness
912013021339408/22/13 Dispensing device
922013021765808/22/13 Pyrazole compounds acting against allergic, inflammatory and immune disorders
932013021089208/15/13 Method of treatment
942013020370508/08/13 Pyrazole compounds acting against allergic, immune and inflammatory conditions
952013020380208/08/13 3 -amino- pyrazole derivatives useful against tuberculosis
962013019641208/01/13 Magi polynucleotides, polypetides, and antibodies
972013018925507/25/13 Fusions and conjugates of insulinotropic agents
982013013133805/23/13 Substituted diketopiperazines as oxytocin antagonists
992013011813205/16/13 Machine and pharmaceutical and pharmaceutical-like product assembly
1002013010969005/02/13 Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
1012013010278304/25/13 Substituted diketopiperazines and their use as oxytocin antagonists
1022013007819803/28/13 Novel use
1032013005337502/28/13 Amino-quinolines as kinase inhibitors
1042013003947002/14/13 Sample plate for an x-ray powder diffraction apparatus
1052013004098402/14/13 7-(lh-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors
1062013003001201/31/13 Compounds
1072013003001501/31/13 Muscarinic acetylcholine receptor antagonists
1082013002354101/24/13 Voltage-gated sodium channel blockers
1092013001249101/10/13 Pyrimidine derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
1102012031620212/13/12 Compounds which have activity at m1 receptor and their uses in medicine
1112012030972512/06/12 Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
1122012030978912/06/12 Compounds which have activity at m1 receptor and their uses in medicine
1132012028854411/15/12 Novel retigabine composition
1142012027727911/01/12 Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions
1152012025146810/04/12 Compositions comprising alginates with high guluronic acid/mannuronic acid ratio for use in the treatment of dentine hypersensitivity
1162012024074209/27/12 Novel device
1172012024517109/27/12 Benzpyrazole derivatives as inhibitors of pi3 kinases
1182012023855909/20/12 Novel compounds
1192012023857109/20/12 Indazole derivatives as pi 3-kinase
1202012023206109/13/12 Novel compounds
1212012020774908/16/12 Dosing regimen
1222012020281108/09/12 Novel compounds
1232012015744606/21/12 Medical use
1242012015749106/21/12 Muscarinic acetylcholine receptor antagonists
1252012015749206/21/12 Antibiotic drug
1262012014971106/14/12 Piperidine derivatives used as orexin antagonists
1272012014973106/14/12 New medical use
1282012012868905/24/12 Anti-il-23 immunoglobulins
1292012012977805/24/12 Ligand that bind tgf-beta receptor rii
1302012011464705/10/12 Anti-serum album single variable domains
1312012010013704/26/12 Immunoglobulins
1322012010108304/26/12 S1p1 agonists comprising a bicyclic n-containing ring
1332012010108604/26/12 Thiadiazole derivatives and their use for the treatment of disorders mediated by s1p1 receptors
1342012010112404/26/12 1,2,4-oxadiazol derivatives, their pharmaceutical compositions and their use as sphingosine 1-phosphate 1 receptor agonists
1352012010113404/26/12 5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists
1362012010113604/26/12 5-membered heteroaryl derivatives used as sphingosine 1- phosphate receptor agonists
1372012006517703/15/12 Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
1382012005896303/08/12 Macrolides with anti-inflammatory activity
1392012004625802/23/12 Novel crystalline pharmaceutical product
1402012004646902/23/12 Process for the preparation of a biphenyl-2-yl carbamic acid ester
1412012003982002/16/12 Antibacterial composition comprising 4-isopropyl-3-methylphenol and zinc ions
1422012004099102/16/12 3-azabicyclo [4.1.0] heptanes used as orexin antagonists
1432012004102702/16/12 Benzimidazoles which have activity at m1 receptor and their uses in medicine
1442012004102802/16/12 Benzimidazoles which have activity at m1 receptor and their uses in medicine
1452012003431202/09/12 4-isopropyl-3-methylphenol for the treatment of inflammation
1462012000632201/12/12 Drug dispenser
1472012000422901/05/12 Substituted diketopiperazines and their use as oxytocin antagonists
1482011031937112/29/11 Pharmaceutical formulations comprising 4-hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
1492011030569212/15/11 Antigen-binding contructs
1502011030569312/15/11 Anitigen-binding constructs
1512011028809811/24/11 Novel compounds
1522011028190911/17/11 Substituted quinoline derivatives as h1 receptor antagonists
1532011027565511/10/11 Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
1542011027566111/10/11 Tricyclic nitrogen compounds used as antibacterials
1552011026973811/03/11 Compounds
1562011026997011/03/11 Phenethanolamine derivatives for treatment of respiratory diseases
1572011026358810/27/11 Tricyclic compounds as glutamate receptor modulators
1582011025375210/20/11 Nozzle for a nasal inhaler
1592011025607410/20/11 Novel use
1602011024547010/06/11 Immunoglobulins
1612011023779209/29/11 Quinoline derivatives and their use as 5-ht6 ligands
1622011019027408/04/11 Salt of, and processes for the preparation of, 1-isopropyl-4-hexahydro-1h-1,4-diazepine
1632011017806307/21/11 Benzpyrazol derivatives as inhibitors of pi3 kinases
1642011016615007/07/11 Anhydrous crystal form of ovrepitant maleate
1652011015087106/23/11 Treatment of an autoimmune disease using il-18 antagonists
1662011015226206/23/11 Novel compounds
1672011014282406/16/11 Antibodies against amyloid-beta peptide
1682011014415106/16/11 Novel process, salts, composition and use
1692011013569506/09/11 Oral dosage form for controlled drug release
1702011013042306/02/11 Compounds which have activity at m1 receptor and their uses in medicine
1712011011719005/19/11 Pharmaceutical formulations
1722011011826105/19/11 Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
1732011006164603/17/11 Drug dispenser
1742011006474003/17/11 Antigen binding proteins
1752011006572503/17/11 Triazole amide derivatives for use in therapy
1762011005916703/10/11 Encapsulation of biologically active agents
1772011005997903/10/11 Piperidine/cyclohexane carboxamide derivatives for use as vanilloid receptor modulators
1782011004502702/24/11 Adjuvant
1792011004613702/24/11 Pyrazole derivatives as p2x7 modulators
1802011003452402/10/11 Hemi-fumarate salt of a 1,3,4-thiadiazolyl derivative as modulator of the sphingosine 1-phosphate receptor
1812011002157801/27/11 Compounds which potentiate the ampa receptor and uses thereof in medicine
1822011000939401/13/11 Tricyclic nitrogen compounds and their use as antibacterial agents
1832011000963101/13/11 Phenethanolamine derivatives for treatment of respiratory diseases
1842010032999612/30/10 Novel combination of therapeutic agents
1852010032402212/23/10 Novel compounds
1862010031657912/16/10 Novel use of alkyl phosphate esters
1872010031766612/16/10 Composition comprising an nk-1 receptor antagonist and an ssri for the treatment of tinnitus and hearing loss
1882010031767212/16/10 Monomaleate monohydrate salt of a 5ht1a receptor antagonist
1892010030808212/09/10 Dispensing device
1902010031170612/09/10 Method of treatment of allergic rhinitis
1912010031173412/09/10 Spiro compounds useful as antagonists of the h1 receptor
1922010030382112/02/10 Immunoglobulins
1932010030510712/02/10 Quinoline derivatives and their use as 5-ht6 ligands
1942010030512712/02/10 Novel compounds
1952010030516612/02/10 Novel compounds
1962010029222411/18/10 Isothiazolidine 1,1-dioxide and tetrahydro-2h-1,2-thiazine 1,1-dioxide derivatives as p2x7 modulators
1972010029229511/18/10 5-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators
1982010028615211/11/10 N-phenyl hydrazides as modulators of the ghrelin receptor
1992010027590911/04/10 Actuator for an inhaler
2002010027385310/28/10 Novel isoindol derivatives as ep4 receptor agonists
2012010026769110/21/10 Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
2022010026773410/21/10 N-[(3,5-dichlorophenyl)methyl]-2-(4-methyl-1-piperazinyl)-2-(1-naphthalenyl)ethanamide as ghrelin receptor modulator
2032010025619910/07/10 Crystalline form of an antimalarial compound
2042010025691910/07/10 Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
2052010023966609/23/10 Process for producing mouldings from (meth) acrylate copolymers by means of injection moulding
2062010022418509/09/10 Actuator for an inhaler
2072010022234909/02/10 Quinoline derivatives used to treat inflammatory and allergic diseases
2082010021679908/26/10 Phthalazine and pyrido[3,4-d]pyridazine compounds as h1 receptor antagonists
2092010021683708/26/10 Glycine transport inhibitors
2102010021067208/19/10 Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
2112010020325608/12/10 Method and the application of powder material to substrates
2122010020424208/12/10 Piperazine derivative having affinity for the histamine h3 receptor
2132010020427308/12/10 Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
2142010019767908/05/10 Compounds
2152010019769908/05/10 I-oxa-3-azaspiro (4.5) decan-2-one and 1-oxa-3, 8-diazaspiro (4.5) decan-2-one derivatives for the treatment of eating disorders
2162010019076407/29/10 Novel compounds
2172010018477007/22/10 Compounds
2182010018499607/22/10 Process of amide formation
2192010017569807/15/10 Capsule
2202010017406507/08/10 Compounds
2212010014809106/17/10 Method and system for rapid phase luminescense spectroscopy analysis
2222010015219506/17/10 Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
2232010014401606/10/10 Apparatus for the disruption of animal cells
2242010014475506/10/10 Novel compounds
2252010014482906/10/10 Novel receptor antagonists and their methods of use
2262010014504006/10/10 Benzazepine derivatives for the treatment of neurological disorders
2272010013727606/03/10 Compounds which potentiate ampa receptor and uses thereof in medicine
2282010013735306/03/10 Tricyclic compounds as antibacterials
2292010013737806/03/10 Pyridine compounds for the treatment of prostaglandin mediated diseases
2302010013742806/03/10 Oxygen containing heterocycles as glycine transporter inhibiting compounds
2312010013058305/27/10 Prolinamide derivatives as modulators of voltage-gated sodium channels
2322010011352105/06/10 Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2s-phenylpiperidin-3s-yl-)
2332010011352805/06/10 Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
2342010011379605/06/10 Indole derivatives as s1p1 receptor
2352010010565204/29/10 Purines as cysteine protease inhibitors
2362010010568804/29/10 Pharmaceutical compositions comprising 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazine or r(-)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine and an nk1
2372010010575404/29/10 5-(4phenyl)prolinamide for treatment of epilepsy
2382010008742404/08/10 Tricyclic nitrogen containing heterocycles as antibacterial agents
2392010008750204/08/10 Indazoles used to treat estrogen receptor beta mediated disorders
2402010008766704/08/10 Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
2412010008183004/01/10 Methods of synthesizing n-hydroxysuccinimidyl carbonates
2422010007595303/25/10 Substituted piperazines, (1,4) diazepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists
2432010007598203/25/10 Pyridinone derivative for the treatment of premature ejaculation
2442010006816603/18/10 Oral composition comprising dimethicone copolyol
2452010006940903/18/10 "novel compounds"
2462010006941603/18/10 Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine d3 receptors
2472010005905203/11/10 Sheet driver for use in a drug dispenser
2482010006309703/11/10 Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine d3 receptors
2492010005650203/04/10 Compounds



ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Glaxo Group Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Glaxo Group Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###